IBI363 Clinical Trials
6 recruitingDrug
Phase 25Phase 12
Showing 1–6 of 6 trials
Recruiting
Phase 2
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.170 enrolled1 locationNCT07122687
Recruiting
Phase 2
A Study of IBI363 in Subjects With Advanced Melanoma
Melanoma
Innovent Biologics (Suzhou) Co. Ltd.150 enrolled12 locationsNCT06081920
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
Melanoma
Innovent Biologics (Suzhou) Co. Ltd.180 enrolled31 locationsNCT06797297
Recruiting
Phase 2
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Colorectal, CancerMelanomaNon-small Cell Lung Cancer+1 more
Innovent Biologics (Suzhou) Co. Ltd.178 enrolled9 locationsNCT06281678
Recruiting
Phase 1
Study of IBI363 in Patients with Advanced First-line Gastric Cancer
IBI363 + Chemotherapy
Xiangdong Cheng40 enrolled1 locationNCT06610799
Recruiting
Phase 1Phase 2
The Efficacy and Safety of IBI363 in Solid Tumors
Advanced Solid Tumor
Hunan Province Tumor Hospital430 enrolled1 locationNCT06081907